Skip to main content
SpringerLink
Log in

Prevalence of vertebral fractures and serum sclerostin levels in acromegaly

  • Original Article
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Objective

An increased prevalence of vertebral fractures (VFs) has been reported in previous studies. The aim of this study was to evaluate the association between bone mineral density (BMD), bone turnover markers, serum sclerostin levels, and vertebral fractures (VFs) in acromegaly patients. We also evaluated the effects of gonadal status, disease activity, treatment modality, age, sex, and body mass index (BMI) on skeletal endpoints.

Design

Case–control study.

Patients and measurements

Seventy acromegaly patients (M/F:36/34, mean age 45.5 ± 11.9 years) and 70 controls (M/F:31/39; mean age 45.66 ± 11.9 years) were included. VFs, BMD, calcium metabolism, markers of bone turnover, and sclerostin levels were evaluated. BMD was measured by dual-energy X-ray absorptiometry (Hologic QDR 4500). Conventional lateral radiography of the spine was performed and the Genant method was used for the assessment of fractures of T4–L5 vertebrae.

Results

The prevalence of vertebral fractures was higher in acromegalic patients as compared with the control group (72.9 vs. 20%; p < 0.001). Serum phosphate (P) levels (3.46 ± 0.59 mg/dl vs. 3.11 ± 0.44 mg/dl; p < 0.001) and b-cross laps (CTx) levels (0.47 µg/l, range 0.04–2.38 vs. 0.28 µg/l, range 0.11–0.80; p < 0.001) were significantly higher in acromegaly patients than control subjects. Serum sclerostin levels were similar between either acromegaly patients and control subjects or acromegaly patients with VF and without VF. In the means of treatment modality, VFs were more frequent in patients treated with adjuvant gamma knife radiosurgery (GKS) (p = 0.07). In the binary logistic regression analysis, the age of the acromegaly patients, the presence of hypogonadism, and GKS treatment were the factors significantly correlated with the occurrence of spinal fractures.

Conclusions

The prevalence of VFs in patients with acromegaly is higher than in control subjects. Since advanced age, the presence of hypogonadism and GKS treatment were the factors predicting VFs in acromegaly; radiological evaluations should be considered as an emerging tool especially in those patients. Although markers of bone turnover elevated in acromegaly, they were not useful for the prediction of fractures. Serum sclerostin levels showed no discrepancy between the two groups and further studies are required for assessment of sclerostin role in this form of secondary osteoporosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. A. Colao, L.F.S. Grasso, A. Giustina, S. Melmed, P. Chanson, A.M. Pereira et al. Acromegaly. Nat. Rev. Dis. Prim. 5(1), 20 (2019)

    Article  Google Scholar 

  2. M. Cellini, E. Biamonte, M. Mazza, N. Trenti, P. Ragucci, D. Milani et al. Vertebral fractures associated with spinal sagittal imbalance and quality of life in acromegaly: a radiographic study with Eos 2d/3d technology. Neuroendocrinology (2020)

  3. G. Mazziotti, A.G.A. Lania, E. Canalis, Management of endocrine disease: bone disorders associated with acromegaly: mechanisms and treatment. Eur. J. Endocrinol. 181(2), R45–R56 (2019)

    Article  CAS  Google Scholar 

  4. A. Giustina, G. Mazziotti, E. Canalis, Growth hormone, insulin-like growth factors, and the skeleton. Endocr. Rev. 29(5), 535–59 (2008)

    Article  CAS  Google Scholar 

  5. S. Bonadonna, G. Mazziotti, M. Nuzzo, A. Bianchi, A. Fusco, L. De Marinis et al. Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. J. Bone Min. Res. 20(10), 1837–44 (2005)

    Article  Google Scholar 

  6. G. Mazziotti, E. Biagioli, F. Maffezzoni, M. Spinello, V. Serra, R. Maroldi et al. Bone turnover, bone mineral density, and fracture risk in acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab. 100(2), 384–94 (2015)

    Article  CAS  Google Scholar 

  7. G. Mazziotti, A. Bianchi, S. Bonadonna, V. Cimino, I. Patelli, A. Fusco et al. Prevalence of vertebral fractures in men with acromegaly. J. Clin. Endocrinol. Metab. 93(12), 4649–55 (2008)

    Article  CAS  Google Scholar 

  8. M. Wassenaar, N. Biermasz, N. Hamdy, M. Zillikens, J. Van Meurs, F. Rivadeneira et al. High prevalence of vertebral fractures despite normal bone mineral density in patients with long-term controlled acromegaly. Eur. J. Endocrinol. 164(4), 475 (2011)

    Article  CAS  Google Scholar 

  9. K. Claessen, H. Kroon, A. Pereira, N. Appelman-Dijkstra, M. Verstegen, M. Kloppenburg et al. Progression of vertebral fractures despite long-term biochemical control of acromegaly: a prospective follow-up study. J. Clin. Endocrinol. Metab. 98(12), 4808–15 (2013)

    Article  CAS  Google Scholar 

  10. G. Mazziotti, A. Bianchi, T. Porcelli, M. Mormando, F. Maffezzoni, A. Cristiano et al. Vertebral fractures in patients with acromegaly: a 3-year prospective study. J. Clin. Endocrinol. Metab. 98(8), 3402–10 (2013)

    Article  CAS  Google Scholar 

  11. A. Giustina, A. Barkan, A. Beckers, N. Biermasz, B.M.K. Biller, C. Boguszewski et al. A consensus on the diagnosis and treatment of acromegaly comorbidities: an update. J. Clin. Endocrinol. Metab. 105, 4 (2020)

    Article  Google Scholar 

  12. J. Delgado-Calle, A.Y. Sato, T. Bellido, Role and mechanism of action of sclerostin in bone. Bone 96, 29–37 (2017)

    Article  CAS  Google Scholar 

  13. A.R. Wijenayaka, M. Kogawa, H.P. Lim, L.F. Bonewald, D.M. Findlay, G.J. Atkins, Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS ONE 6(10), e25900 (2011)

    Article  CAS  Google Scholar 

  14. G. Holdsworth, S.J. Roberts, H.Z. Ke, Novel actions of sclerostin on bone. J. Mol. Endocrinol. 62(2), R167–R85 (2019)

    Article  CAS  Google Scholar 

  15. M. McLung, A. Frauer, S. Boonen, Romosozumab in postmenopausal women with low bone mineral density. N. Engl. J. Med 370(5), 412–20 (2014)

    Article  Google Scholar 

  16. K.A. Carpenter, R.D. Ross, Sclerostin antibody treatment increases bone mass and normalizes circulating phosphate levels in growing Hyp mice. J. Bone Miner. Res. 35(3), 596–607 (2020)

    Article  CAS  Google Scholar 

  17. H.K. Genant, C.Y. Wu, C. Van Kuijk, M.C. Nevitt, Vertebral fracture assessment using a semiquantitative technique. J. Bone Miner. Res. 8(9), 1137–48 (1993)

    Article  CAS  Google Scholar 

  18. M. Madeira, L.V. Neto, C.H. Torres, L.M.C. de Mendonça, M.R. Gadelha, M.L.F. de Farias, Vertebral fracture assessment in acromegaly. J. Clin. Densitom. 16(2), 238–43 (2013)

    Article  Google Scholar 

  19. A. Giustina, A. Barkan, A. Beckers, N. Biermasz, B.M. Biller, C. Boguszewski et al. A consensus on the diagnosis and treatment of acromegaly comorbidities: an update. J. Clin. Endocrinol. Metab. 105(4), e937–e46 (2020)

    Article  Google Scholar 

  20. Z. Pekkolay, F. Kılınç, N. Gozel, E. Önalan, A.K. Tuzcu, Increased serum sclerostin levels in patients with active acromegaly. J. Clin. Endocrinol. Metab. 105(3), 920–4 (2020)

    Article  Google Scholar 

  21. J. Halupczok-Żyła, A. Jawiarczyk-Przybyłowska, A. Zembska, M. Bolanowski (eds) Sclerostin and fracture risk assessment in acromegaly. 21st European Congress of Endocrinology (BioScientifica, 2019)

  22. B.M. Tang, G.D. Eslick, C. Nowson, C. Smith, A. Bensoussan, Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 370(9588), 657–66 (2007)

    Article  CAS  Google Scholar 

  23. S. Chiloiro, A. Giampietro, S. Frara, C. Bima, F. Donfrancesco, C.M. Fleseriu et al. Effects of pegvisomant and pasireotide LAR on vertebral fractures in acromegaly resistant to first-generation SRLs. J. Clin. Endocrinol. Metab. 105(3), e100–e7 (2020)

    Article  Google Scholar 

  24. M.M. Uygur, O. Deyneli, D.G. Yavuz, Long-term endocrinological outcomes of gamma knife radiosurgery in acromegaly patients. Growth Horm. IGF Res. 55, 101335 (2020)

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology and Metabolism, Marmara University School of Medicine, Istanbul, Turkey

    Meliha Melin Uygur, Dilek Dereli Yazıcı & Dilek Gogas Yavuz

  2. Department of Radiology, Marmara University School of Medicine, Istanbul, Turkey

    Onur Buğdaycı

Authors
  1. Meliha Melin Uygur
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dilek Dereli Yazıcı
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Onur Buğdaycı
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dilek Gogas Yavuz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Meliha Melin Uygur.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Uygur, M.M., Yazıcı, D.D., Buğdaycı, O. et al. Prevalence of vertebral fractures and serum sclerostin levels in acromegaly. Endocrine 73, 667–673 (2021). https://doi.org/10.1007/s12020-021-02751-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-021-02751-9

Keywords

Search

Navigation